AlloVir logo
AlloVir ALVR
report update icon

Quarterly report 2026-Q3
added 11-10-2026

AlloVir EPS Ratio | ALVR

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio AlloVir

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-2.85 -51.8 -42.1 -2.2 -2.74 -2.59 -18.5 - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-2.2 -51.8 -17.5

Quarterly EPS Ratio AlloVir

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-0.46 -0.48 -0.46 -0.44 -0.64 -0.61 -2.52 - -28.2 -4.26 -2.6 -40.8 -0.39 -0.48 -0.44 -0.37 -0.5 -0.69 -0.69 -0.92 -0.72 -0.6 -0.5 0.34 -0.58 -4.43 -4.21 - -4.97 -5.05 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
0.34 -40.8 -3.81

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
Repare Therapeutics Repare Therapeutics
RPTX
-2 - - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
-1.46 - 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
-104 - - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
-1.29 - - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
-2.76 - 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
-2.06 - 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
-2.96 - - $ 13 M usaUSA
Lyra Therapeutics Lyra Therapeutics
LYRA
-18.6 - - $ 24.9 M usaUSA
Brickell Biotech Brickell Biotech
BBI
-1.06 - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-0.76 - - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
-0.64 - - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
-1.98 - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
-0.47 - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
-3.35 - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
-3.19 - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
-1.34 $ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-0.47 - 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
-10.4 - -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
4.87 - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
-0.08 - -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-0.93 - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
2.39 $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
-1.25 $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
0.07 - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
-4.18 - - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
1.66 - -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
-1.49 - -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
-2.29 - - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
-23.8 - 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
-2.22 - -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-2.08 - -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
-7.18 - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
-0.27 - - $ 69.7 B britainBritain
Atreca Atreca
BCEL
-2.52 - -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
0.12 - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
0.68 - - $ 109 M usaUSA
Akouos Akouos
AKUS
-2.52 - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
-0.88 - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
-3.41 - -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
-26.8 - - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
-1.26 - - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
-2.84 - -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
-0.56 - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
-0.08 - - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
-0.87 - 31.87 % $ 1.61 M usaUSA